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Background: The relative risk of developing idiopathic PD is 1.5 times greater in men than in women, but
an increased female prevalence in LRRK2-carriers has been described in the Ashkenazi Jewish popula-
tion. We report an update about the frequency of major LRRK2 mutations in a large series of consecutive
patients with Parkinson’s disease (PD), including extensive characterization of clinical features. In
particular, we investigated gender-related differences in motor and non-motor symptoms in the LRRK2
population.
Methods: 2976 unrelated consecutive Italian patients with degenerative Parkinsonism were screened for
mutations on exon 41 (G2019S, I2020T) and a subgroup of 1190 patients for mutations on exon 31
(R1441C/G/H). Demographic and clinical features were compared between LRRK2-carriers and non-
carriers, and between male and female LRRK2 mutation carriers.
Results: LRRK2 mutations were identiﬁed in 40 of 2523 PD patients (1.6%) and not in other primary
parkinsonian syndromes. No major clinical differences were found between LRRK2-carriers and non-
carriers. We found a novel I2020L missense variant, predicted to be pathogenic. Female gender was
more common amongst carriers than non-carriers (57% vs. 40%; p ¼ 0.01), without any gender-related
difference in clinical features. Family history of PD was more common in women in the whole PD
group, regardless of their LRRK2 status.
Conclusions: PD patients with LRRK2 mutations are more likely to be women, suggesting a stronger
genetic load compared to idiopathic PD. Further studies are needed to elucidate whether there is a
different effect of gender on the balance between genetic and environmental factors in the pathogenesis
of PD.
 2014 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/3.0/).1. Introduction
Leucine-rich Repeat Kinase 2 (LRRK2) is one of the genes that is
most frequently involved in Parkinson’s disease (PD)[e-1]. Many
variants in this gene have been described, but only a few of them
are certainly pathogenic, including mutations G2019S and R1441C/
G/H. The most common mutation is G2019S, whose frequencyx: þ39 02 5799 3468.
tefano.goldwurm@gmail.com
r Ltd. This is an open access articlevaries considerably among populations [e-1]. Penetrance of LRRK2
mutations is incomplete and age-related [1].
Recent studies have shown that gender distribution is even
among Ashkenazi Jews LRRK2 carriers [2e4] and in other genetic
forms of PD [5]. These studies also suggested that there may be
gender-related differences in the balance between genetic and
environmental factors, the genetic load being heavier in women
than in men [6]. On the other hand, it is still debated whether PD
LRRK2 carriers display a distinctive clinical phenotype compared to
idiopathic PD or not [e-1ee-4].
We compared demographic and clinical features between car-
riers and non-carriers to shed light on the possible impact of LRRK2under the CC BY license (http://creativecommons.org/licenses/by/3.0/).
Table 1
LRRK2 mutations identiﬁed in PD patients.
N of PD patients Mutation N carriers (%)
Exon 41 2523 G2019S 34 (1.35%)a
I2020L 1 (0.04%)
Exon 31 1088 R1441C 4 (0.37%)b
R1441H 1 (0.09%)
Total 2523 All 40 (1.59%)
a One patient was homozygote for G2019S, and one was carrier of the GBA-N370S
mutation.
b One patient was carrier of the GBA-N370S mutation.
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LRRK2 status inﬂuences gender distribution and PD phenotype.
2. Methods
2.1. Subjects
We studied 2976 unrelated consecutive patients with degenerative parkin-
sonism, who contributed to the ‘Parkinson Institute Biobank’ (http://www.
parkinsonbiobank.com) from June-2002 to January-2011. All patients were
enrolled consecutively, not selected for any clinical or familial feature. A ﬁrst group
of 1245 patients was described elsewhere [7]. Here, we report an update on 1734
additional patients, reaching a total of 2976 unrelated consecutive patients. All pa-
tients were tested for the major LRRK2 mutation G2019S in exon 41. Exon 31, con-
taining the mutations R1441C/G/H, was analyzed in a subgroup of 1190 patients (a
ﬁrst group of consecutive patients and then only familial cases), out of whom 1088
had PD (428 familial and 660 sporadic cases). In addition, when LRRK2-mutations
were identiﬁed in a proband, we studied all available familymembers with a deﬁnite
PD diagnosis. Thus, we enrolled 10 additional living relatives affected by PD and
carriers of the G2019S mutation from nine families. Patients found to be carriers of
mutations in any other PD-related genes (see Supplementary material) were not
excluded from LRRK2 genetic analysis. However, to minimize confounding effects on
the phenotype, we excluded such patients from the comparative analysis of clinical
features.
Clinical diagnosis wasmade according to established diagnostic criteria [e-5]. All
the 2976 patients had a diagnosis of primary degenerative parkinsonism: 2523
fulﬁlled criteria for PD, 53 for Dementia with Lewy Bodies, 128 for Multiple System
Atrophy, 14 for Frontotemporal Dementia, 103 for Progressive Supranuclear Palsy,
and 33 for Corticobasal Degeneration. In the remaining 122 patients the clinical
diagnosis was still uncertain and reported as Undeﬁned Primary Parkinsonism.
Among the 2523 PD patients, 1488 were male (59%), mean age at onset was 55.76
years (range 14e87; SD  10.94), mean disease duration was 14.12 years (range 2e
56; SD  6.75).
Family history in LRRK2-carriers was evaluated during formal genetic coun-
seling. Proband relatives with possible parkinsonism not available for neurological
examination were assumed to have PD only in case of previous diagnosis and when
prescription of dopaminergic therapy was reported. In non-carriers, family history
was collected by means of a questionnaire. Formal genetic counseling sessions
occurred in most cases when a relative was reported to be affected by PD. Patients
were classiﬁed as “familial” if at least one among their 1st, 2nd, or 3rd degree rel-
atives had a formal diagnosis of PD.
Clinical features of LRRK2-carriers were compared to those of patients whose
molecular analysis was negative for the major LRRK2 mutations and for other mu-
tations in known PD genes. Demographic and clinical data were collected from all
patients, including the latest Uniﬁed Parkinson’s Disease Rating Scale (UPDRS)
scores from part I to III in the medication-On and -Off state, and the Hoehn and Yahr
stage. Major milestones of PD progression were explored by transforming speciﬁc
UPDRS items into dichotomous variables, i.e. falls (item 13, score  2), postural
instability (score 2 for item 30), non-levodopa-responsive freezing of gait (item 14,
score  2), dysphagia (item 7, score  2) and speech difﬁculties (item 18, score  2).
The study was approved by the local Ethics Committee and written informed
consent was obtained from all subjects.
2.2. Mutation analysis
R1441C/G/H, G2019S and I2020T mutations were analyzed with standard
methods (see Supplementary materials). LRRK2 haplotype was analyzed in all
G2019S carriers (Table e-1).
2.3. Statistical analysis
We compared demographic and clinical variables between LRRK2-carriers and
non-carriers, and we also tested gender differences between groups, using para-
metric and non parametric tests as appropriate. In order to better characterize group
differences, six variables (gender, asymmetry at onset, smoking, age at onset, disease
duration, levodopa latency) were analyzed in a multivariate context through
multivariate logistic regression, with the presence of LRRK2 mutations as dichoto-
mous response variable. Furthermore, we compared motor phenotype and dichot-
omous values of selected UPDRS items. Statistical analyses were conducted using R
statistical software (see Supplementary material).
3. Results
3.1. Mutation prevalence
Among the 2523 unrelated consecutive PD patients, 40 (1.6%)
resulted to be carriers of LRRK2 mutations, G2019S being the most
frequent (1.35%; Table 1). No mutation was found in all the other
patients with alternative clinical diagnoses (N ¼ 453). LRRK2mutations were signiﬁcantly more frequent in familial than in
sporadic PD cases (Table e-2). In all G2019S carriers, genotypes
were compatible with the common haplotype (haplotype n.1).
We found several cases with rare genotypes (detailed case re-
ports available as Supplementary material). Notably, one patient
was carrier of the novel I2020L missense variant. The I2020 residue
is involved in a well-knownmutation (I2020T), and several in silico
tools (PolyPhen, SIFT, Mutation Taster) predict that the I2020L
change is damaging (Table e-3). Therefore, we considered this new
variant as a mutation. Finally, we disclosed two synonymous vari-
ants in the heterozygous state: c.6054C > T (p.Y2018Y), which has
already been described [2], and the novel c.6021C > T (p.P2007P)
variant.3.2. Clinical features and gender effect
A total of 49 PD LRRK2 carriers were included in the analysis of
clinical features, resulting from the sum of N ¼ 40 (24F/16M) from
the case series and N ¼ 10 (6M/4F) affected living relatives,
excluding N ¼ 1 patient with clinical diagnosis of PD whose post-
mortem examination revealed a PSP-like tauopathy (see
Supplementary material). Demographic and clinical features of
LRRK2-carriers did not differ from those of non-carriers (Table 2).
Gender distribution resulted to be the only differential feature
between the two groups, as most of the carriers were female (57%
vs. 40%, p ¼ 0.0101). This difference remained signiﬁcant after
excluding the 10 living relatives recruited in addition to the case
series (60% vs. 40%, p ¼ 0.015). After adjusting for disease duration
and age, the frequency and severity of major motor and non-motor
symptoms were similar.
We compared carrier females to carrier males, and against the
respective non-carrier group (Table 2). We did not ﬁnd any signif-
icant difference, with exception of smoking (more common in
males in both groups). Major milestones of PD progression (falls,
postural instability, freezing of gait, dysphagia and speech difﬁ-
culties) did not showany signiﬁcant gender-related difference, both
in the Off- and in the On-state (data not shown).
In an attempt to evaluate the genetic component for PD inmales
and females regardless of genetic status, we compared family his-
tory in all PD cases (N ¼ 2523). Women reported a family history of
parkinsonism more frequently than men, but the difference was
statistically signiﬁcant only considering all relatives up to 3rd de-
gree relatives (p¼ 0.017). However, a clear trendwas evident also in
1st degree relatives (p ¼ 0.058; Supplementary Table e-4).4. Discussion
To the best of our knowledge, this is the largest consecutive
series of patients with primary parkinsonism collected at a single
clinical referral centre and tested systematically for major LRRK2
mutations. Our ﬁndings conﬁrm that G2019S is the most common
mutation in the Italian PD population, while it is virtually absent in
Table 2
Motor clinical features of PD patients according to genetic status (LRRK2-carriers vs. non-carriers) and gender.
LRRK2-carrier Non-carrier LRRK2-carrier
female
LRRK2-carrier
male
Non-carrier
female
Non-carrier
male
Demographic and clinical variables N ¼ 49 N ¼ 2343 p valuec N ¼ 28 N ¼ 21 N ¼ 947 N ¼ 1396
Female gender, n (%) 28 (57%) 947 (40%) 0.0101
Age at onset 55.82  11 56.37  10 NS 56.39  12.14 55.05  11.50 57.13  10.64 55.84  10.59
Disease duration 12.33  6.50 11.64  6.56 NS 12.50  7.01 12.10  5.92 11.82  6.74 11.52  6.43
Levodopa latencya 1.93  1.83 2.63  2.82 NS 1.85  1.75 2.05  1.99 2.65  3.06 2.61  2.65
Asymmetry at onset, n/total (%) 46/49 (94%) 1975/2281 (87%) NS 26/28 (93%) 20/21 (95%) 791/919 (86%) 1184/1362 (87%)
Never-smokerb, n/total (%) 29/49 (59%) 1294/2037 (64%) NS 21/28 (75%)e 8/21 (38%)e 642/802 (80%) 652/1235 (53%)
UPDRS on N ¼ 48 N ¼ 2101 p valued N ¼ 28 N ¼ 20 N ¼ 858 N ¼ 1243
Age at UPDRS assessment 67.29  10.21 67.59  10.18 NS 68.11  9.69 66.15  11.05 68.44  10.22 67.00  10.12
Disease duration at UPDRS assessment 11.79  6.60 11.20  6.61 NS 11.93  6.97 11.60  6.21 11.35  6.75 11.10  6.51
Part I e Mentation 2.79  2.75 3.03  2.42 NS 2.92  2.59 2.59  2.18 3.00  2.62 3.05  2.73
Part II e ADL 13.95  8.14 13.13  7.33 NS 13.81  8.70 14.18  7.46 12.80  7.45 13.34  7.25
Part III e Motor score 24.69  14.74 24.01  12.92 NS 25.57  16.32 23.45  12.52 24.04  13.53 24.00  12.49
Motor Phenotype PIGD-IND-TD, % 81-7-12 76-7-17 NS 88-4-8 70-12-18 80-4-16 78-4-18
Hoehn/Yahr Stage 2.56  0.96 2.5  0.87 NS 2.70  1.04 2.38  0.83 2.57  0.92 2.45  8.83
UPDRS off N ¼ 33 N ¼ 591 p valued N ¼ 20 N ¼ 13 N ¼ 226 N ¼ 365
Age at UPDRS assessment 64.48  10.38 66.99  9.61 NS 65.15  10.06 63.46  11.21 68.21  9.65 66.25  9.53
Disease duration at UPDRS assessment 12.36  6.84 11.47  6.94 NS 12.30  6.37 12.46  7.77 11.53  7.62 11.44  6.50
Part II e ADL 20.11  8.07 15.99  8.18 0.0448 20.53  6.84 19.45  10.01 15.42  8.87 16.34  7.72
Part III e Motor score 34.52  13.51 31.82  13.90 NS 33.80  13.18 35.62  14.47 31.54  15.44 31.99  12.90
Motor Phenotype PIGD-IND-TD, % 82-4-14 71-8-21 NS 88-4-4 72-0-28 72-9-19 70-8-22
Abbreviations: ADL, activities of daily living; IND, indeterminate; PIGD, postural instability and gait difﬁculty; PD, Parkinson’s Disease; TD, tremor-dominant; UPDRS, Uniﬁed
Parkinson’s Disease Rating Scale.
Values are expressed as mean  standard deviation, unless different parameters are speciﬁed.
a Time elapsed (years) from PD onset to initiation of levodopa therapy.
b Data are based on patient self-reporting. Current and former smokers were aggregated into the single category of smokers.
c Multivariate analysis.
d Age at UPDRS assessment and disease duration were always included in the analysis of other variables.
e Female never-smokers were signiﬁcantly more common than male never-smokers among LRRK2-carriers (p ¼ 0.0323). No other signiﬁcant differences were present
between carrier females and carrier males, and versus the respective non-carrier group.
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is more common in women.
Large epidemiological studies have consistently reported a
higher incidence (approx. 1.5 times) of sporadic idiopathic PD in
men than inwomen [8]. Although the basis of this difference has not
been clariﬁed so far, it has been suggested that the predominance in
males is due tomore frequent occupational or recreational exposure
to toxins, but a putative neuroprotective role played by estrogens
has also been suggested [9]. According to Mendelian inheritance,
autosomal genetic forms of PD should followan even distribution of
gender among affected cases. However, LRRK2mutations have a low
life-time penetrance, approximately 30e40% [1]. Therefore, PD in
LRRK2 carriers should still be considered of multifactorial etiology,
the intervention of other genetic and/or environmental factors be-
ing mandatory for the development of disease. Accordingly, we
would expect a similar 60:40male-to-female distribution. However,
this is not the case, as we found a surprising overturn leading to 57%
prevalence in LRRK2 female carriers.
A relatively higher percentage of women amongst LRRK2-car-
riers compared to patients with idiopathic-PD has previously been
reported, but only in the Ashkenazi Jewish population [2e4].
Several other studies have reported that LRRK2 carriers were
mainly female, but the difference between genders did not reach
statistical signiﬁcance, probably because of small sample size [e.g.
Ref. [10]. If LRRK2-carrier women have a greater load than men,
women might be expected to develop disease earlier or progress
faster than men, or both. A recent study on a large LRRK2 PD cohort
conﬁrmed the former hypothesis, demonstrating that onset of
disease occurs 5 years earlier inwomen [11]. On the other hand, our
extensive analysis did not reveal any gender-related difference in
clinical phenotype, including motor and non-motor symptom
severity and measures of disease progression.
In this scenario, one could set forth the hypothesis that this
gender-related effect applies not only to LRRK2 and to other geneticforms of PD [5], but also to sporadic idiopathic PD. To further
explore this hypothesis, we additionally investigated the family
history of PD in the whole cohort of unrelated consecutive PD pa-
tients according to gender. The rationale of this analysis followed
what is usually described in other complex multifactorial inherited
diseases: when subjects of the less commonly affected gender
manifest disease, their relatives are at increased risk because of the
relatively larger ‘genetic load’ overcoming protective factors [12].
Accordingly, we found that PD is more common in the family his-
tory of women than men, regardless of LRRK2 status (Table e-4).
Alternatively, it could be speculated that the LRRK2 mutated
protein may interact with speciﬁc female hormonal or genetic fac-
tors, thus potentially explaining the 57% of female LRRK2-carriers,
even exceeding the expected 50% rate in the presence of autosomal
distribution of the mutation. Our analysis of clinical features
conﬁrmed that female carriers do not have more severe symptoms
than male carriers or female non-carriers and their symptoms do
not differ in any way. Their age at onset is similar and their disease
does not appear to progress more rapidly. Hence, interaction be-
tween LRRK2 and speciﬁc female factors does not seem likely.
Our data support the hypothesis that LRRK2-associated PD
phenotype is not distinguishable from idiopathic PD, as we did not
ﬁnd any remarkable clinical difference between LRRK2-carriers and
non-carriers. The missense variant I2020L, which we found in one
of our patients, involved the same residue of a well-known muta-
tion, I2020T [e-6]. Despite in silico predictions suggesting a
damaging effect, further studies including co-segregation analysis
and functional assays are necessary to include the I2020L variant
among LRRK2 pathogenic mutations.
Several strengths of our study are worth mentioning. First,
LRRK2-carriers were identiﬁed within a large consecutive series of
patients devoid of bias due to pre-selection based on clinical or
demographic features, such as ethnicity, age at onset or family
history. Second, the consecutive enrollment from a single tertiary
R. Cilia et al. / Parkinsonism and Related Disorders 20 (2014) 911e914914centre enabled an exhaustive and standardized clinical assessment
in all cases. Finally, this is the ﬁrst study investigating possible
gender effects on a Caucasian non-Jewish population, including not
only distribution, but also a comprehensive investigation of po-
tential differences in motor and non-motor clinical features.
In conclusion, we conﬁrm a higher frequency of females among
LRRK2-carriers. This might be due to a greater genetic load
compared to males, where environmental factors may play a
prominent role. Further studies are required to investigate this
‘gender effect’ in larger populations, including not only LRRK2-
carriers but also other genetic causes of PD.Financial disclosures relevant for the present article
None of the authors have any disclosures to report.Acknowledgments
The authors thank Margherita Canesi, MD, Claudio Mariani, MD,
Nicoletta Meucci, MD, Claudio Ruffmann, MD, and Silvana Tesei MD
of the Parkinson Institute for patient referral; Jennifer S Hartwig,
MD for help in preparing and editing the manuscript; Elena Bossi
for biobank samples preparation. Finally, the authors thank all
patients and their relatives for their contribution.
C.S. and D.R. are thankful to the ‘Fondazione Grigioni per il
Morbo di Parkinson’, Milan, Italy for ﬁnancial support.
This work was supported by Italian Telethon Foundation (grant
n.GGP11164).
The DNA samples were obtained from the “Parkinson Institute
Biobank” (http://www.parkinsonbiobank.com), member of the
Telethon Network of Genetic Biobank (project n. GTB12001) funded
by TELETHON Italy, and supported by “Fondazione Grigioni per il
Morbo di Parkinson”.Appendix A. Supplementary data
Supplementary data related to this article can be found at http://
dx.doi.org/10.1016/j.parkreldis.2014.04.016.References
[1] Goldwurm S, Tunesi S, Tesei S, Zini M, Sironi F, Primignani P, et al. Kin-cohort
analysis of LRRK2-G2019S penetrance in Parkinson’s disease. Mov Disord
2011;26:2144e5.
[2] Orr-Urtreger A, Shifrin C, Rozovski U, Rosner S, Bercovich D, Gurevich T, et al.
The LRRK2 G2019S mutation in Ashkenazi Jews with Parkinson disease: is
there a gender effect? Neurology 2007;69:1595e602.
[3] Clark LN, Wang Y, Karlins E, Saito L, Mejia-Santana H, Harris J, et al. Frequency
of LRRK2 mutations in early- and late-onset Parkinson disease. Neurology
2006;67:1786e91.
[4] Alcalay RN, Mirelman A, Saunders-Pullman R, Tang MX, Mejia Santana H,
Raymond D, et al. Parkinson disease phenotype in Ashkenazi jews with and
without LRRK2 G2019S. Mov Disord 2013;28(14):1966e71.
[5] Kasten M, Kertelge L, Brüggemann N, van der Vegt J, Schmidt A, Tadic V,
et al. Nonmotor symptoms in genetic Parkinson disease. Arch Neurol
2010;67:670e6.
[6] Saunders-Pullman R, Stanley K, San Luciano M, Barrett MJ, Shanker V,
Raymond D, et al. Gender differences in the risk of familial parkinsonism:
beyond LRRK2? Neurosci Lett 2011;496:125e8.
[7] Goldwurm S, Zini M, Di Fonzo A, De Gaspari D, Siri C, Simons EJ, et al. LRRK2
G2019S mutation and Parkinson’s disease: a clinical, neuropsychological and
neuropsychiatric study in a large Italian sample. Parkinsonism Relat Disord
2006;12:410e9.
[8] Wooten GF, Currie LJ, Bovbjerg VE, Lee JK, Patrie J. Are men at greater risk
for Parkinson’s disease than women? J Neurol Neurosurg Psychiatr 2004;75:
637e9.
[9] Saunders-Pullman R. Estrogens and Parkinson disease: neuroprotective,
symptomatic, neither, or both? Endocrine 2003;21:81e7.
[10] Marras C, Schüle B, Munhoz RP, Rogaeva E, Langston JW, Kasten M, et al.
Phenotype in parkinsonian and nonparkinsonian LRRK2 G2019S mutation
carriers. Neurology 2011;77:325e33.
[11] Trinh J, Amouri R, Duda JE, Morley JF, Read M, Donald A, et al. A comparative
study of Parkinson’s disease and leucine-rich repeat kinase 2 p.G2019S
parkinsonism. Neurobiol Aging 2014;35(5):1125e31.
[12] Silander K, Alanne M, Kristiansson K, Saarela O, Ripatti S, Auro K, et al. Gender
differences in genetic risk proﬁles for cardiovascular disease. PLoS One
2008;3(10):e3615.
